Jinbo Bio-pharmaceutical
the leader in injectable recombinant collagen through its Weiyimei brand of recombinant Type III humanized collagen, reported H1 2025 revenue of RMB 859 million (+42.43% year-on-year) with over 2.7 million units used clinically, though growth decelerated sharply from the 90-180% rates seen in 2023-2024,…
- Country
- China
- Ticker
- 832982.BJ
injectable-filler
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant collagen for cosmetics | fibers-textiles | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.